RU2018113801A - Составы l-орнитин фенилацетата - Google Patents
Составы l-орнитин фенилацетата Download PDFInfo
- Publication number
- RU2018113801A RU2018113801A RU2018113801A RU2018113801A RU2018113801A RU 2018113801 A RU2018113801 A RU 2018113801A RU 2018113801 A RU2018113801 A RU 2018113801A RU 2018113801 A RU2018113801 A RU 2018113801A RU 2018113801 A RU2018113801 A RU 2018113801A
- Authority
- RU
- Russia
- Prior art keywords
- oral administration
- plasma
- pharmaceutical composition
- phenylacetylglutamine
- paragraphs
- Prior art date
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical group NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title claims 10
- 239000000203 mixture Substances 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 41
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims 20
- 229960003424 phenylacetic acid Drugs 0.000 claims 10
- 239000003279 phenylacetic acid Substances 0.000 claims 10
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 6
- 229940049953 phenylacetate Drugs 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 206010020575 Hyperammonaemia Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US62/255,300 | 2015-11-13 | ||
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| US62/276,754 | 2016-01-08 | ||
| US15/133,087 | 2016-04-19 | ||
| US15/133,087 US20160338982A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
| PCT/US2016/061678 WO2017083758A1 (en) | 2015-11-13 | 2016-11-11 | Formulation of l-ornithine phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018113801A true RU2018113801A (ru) | 2019-12-16 |
Family
ID=58695607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018113801A RU2018113801A (ru) | 2015-11-13 | 2016-11-11 | Составы l-орнитин фенилацетата |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3373923A4 (enExample) |
| JP (2) | JP7294807B2 (enExample) |
| KR (2) | KR20250023993A (enExample) |
| CN (2) | CN113768863A (enExample) |
| AU (2) | AU2016353350B2 (enExample) |
| BR (1) | BR112018009349A8 (enExample) |
| CA (1) | CA3004331A1 (enExample) |
| IL (1) | IL258630B2 (enExample) |
| MX (2) | MX389926B (enExample) |
| RU (1) | RU2018113801A (enExample) |
| SG (1) | SG11201802987UA (enExample) |
| WO (1) | WO2017083758A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| SG11202001142VA (en) | 2017-08-14 | 2020-03-30 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
| US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| CN114786662A (zh) * | 2019-10-16 | 2022-07-22 | 欧塞拉治疗有限公司 | 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途 |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| ES2448549T3 (es) | 2004-11-26 | 2014-03-14 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática |
| DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| ES2652187T3 (es) * | 2009-04-03 | 2018-01-31 | Ocera Therapeutics, Inc. | Fenilacetato de l-ornitina y métodos para elaborar el mismo |
| EP2440200B8 (en) * | 2009-06-08 | 2014-10-15 | UCL Business PLC | Treatment of portal hypertension using l-ornithine phenylacetate |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN103705490B (zh) * | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| KR102487376B1 (ko) * | 2014-11-24 | 2023-01-10 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| EP4205735A1 (en) * | 2015-04-20 | 2023-07-05 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| JP6990170B2 (ja) * | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
| EP3352748A4 (en) * | 2015-09-25 | 2019-06-05 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF NEURONAL CELL LOSS BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
-
2016
- 2016-11-11 SG SG11201802987UA patent/SG11201802987UA/en unknown
- 2016-11-11 KR KR1020247042587A patent/KR20250023993A/ko active Pending
- 2016-11-11 CN CN202111062923.6A patent/CN113768863A/zh active Pending
- 2016-11-11 RU RU2018113801A patent/RU2018113801A/ru not_active Application Discontinuation
- 2016-11-11 BR BR112018009349A patent/BR112018009349A8/pt not_active Application Discontinuation
- 2016-11-11 AU AU2016353350A patent/AU2016353350B2/en not_active Ceased
- 2016-11-11 EP EP16865158.6A patent/EP3373923A4/en not_active Withdrawn
- 2016-11-11 KR KR1020187016373A patent/KR20180086431A/ko not_active Ceased
- 2016-11-11 CN CN201680066488.5A patent/CN108366983A/zh active Pending
- 2016-11-11 MX MX2018005088A patent/MX389926B/es unknown
- 2016-11-11 WO PCT/US2016/061678 patent/WO2017083758A1/en not_active Ceased
- 2016-11-11 JP JP2018524369A patent/JP7294807B2/ja active Active
- 2016-11-11 CA CA3004331A patent/CA3004331A1/en not_active Abandoned
-
2018
- 2018-04-11 IL IL258630A patent/IL258630B2/en unknown
- 2018-04-25 MX MX2022001517A patent/MX2022001517A/es unknown
-
2021
- 2021-12-21 AU AU2021290236A patent/AU2021290236A1/en not_active Abandoned
- 2021-12-28 JP JP2021213640A patent/JP2022058446A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL258630B2 (en) | 2023-08-01 |
| CN108366983A (zh) | 2018-08-03 |
| EP3373923A4 (en) | 2019-07-03 |
| MX389926B (es) | 2025-03-20 |
| KR20250023993A (ko) | 2025-02-18 |
| CA3004331A1 (en) | 2017-05-18 |
| SG11201802987UA (en) | 2018-05-30 |
| EP3373923A1 (en) | 2018-09-19 |
| WO2017083758A1 (en) | 2017-05-18 |
| AU2016353350A1 (en) | 2018-05-10 |
| BR112018009349A8 (pt) | 2019-02-26 |
| MX2018005088A (es) | 2019-05-16 |
| BR112018009349A2 (pt) | 2018-11-13 |
| JP2018533601A (ja) | 2018-11-15 |
| MX2022001517A (es) | 2022-11-16 |
| IL258630B1 (en) | 2023-04-01 |
| IL258630A (en) | 2018-06-28 |
| AU2016353350B2 (en) | 2021-09-23 |
| KR20180086431A (ko) | 2018-07-31 |
| CN113768863A (zh) | 2021-12-10 |
| JP7294807B2 (ja) | 2023-06-20 |
| JP2022058446A (ja) | 2022-04-12 |
| AU2021290236A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513171A5 (enExample) | ||
| RU2017137643A (ru) | Составы l-орнитин фенилацетата | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| US9468609B2 (en) | Astaxanthin anti-inflammatory synergistic combinations | |
| WO2009137827A2 (en) | Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation | |
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| JP2015503593A5 (enExample) | ||
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| CA2608651A1 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflammation | |
| RU2016124765A (ru) | ПРИМЕНЕНИЕ ГИНЗЕНОЗИДА Rg3 В ПРИГОТОВЛЕНИИ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ ДЕМЕНЦИИ, И ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ ДЕМЕНЦИИ | |
| US10154980B2 (en) | Anti-inflammatory omega-3 synergistic combinations | |
| JP2018533601A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2015531749A5 (enExample) | ||
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| CN103239439B (zh) | 用于治疗高血脂及动脉粥样硬化的组合物及其用途 | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| KR20130096704A (ko) | 간세포암의 예방 및/또는 치료를 위한 의약 | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| RU2015143993A (ru) | Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением | |
| RU2015115398A (ru) | N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении | |
| FI3886857T3 (fi) | Montelukasti erosiivisen käden nivelrikon hoitoon | |
| JP2022508236A5 (enExample) | ||
| JP2017515858A5 (enExample) | ||
| WO2016153222A3 (ko) | 텔미사르탄 칼륨염을 포함하는 약제학적 조성물 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191112 |